

Literature Review: the use of EFAs in treating various mental disorders

Contents:

1. [ADD and ADHD](#)
2. [Aggression](#)
3. [Alzheimer's Disease](#)
4. [Anxiety](#)
5. [Autism](#)
6. [Bipolar Disorder](#)
7. [Borderline Personality Disorder](#)
8. [Chronic Fatigue Syndrome](#)
9. [Depression](#)
10. [Diabetic Neuropathy](#)
11. [Learning Disabilities](#)
12. [Schizophrenia](#)
13. [Miscellaneous](#)

General Note:

The FDA approval of fish oil at dosages up to 3 grams per day as safe in all age groups can be found in the Federal Register Vol. 62, No. 108, June 5, 1997.

ADD and ADHD

Baumgaertel A. Alternative and controversial treatments for attention-deficit/hyperactivity disorder. *Pediatr Clin North Am* . 1999;46(5):977-992.

Arnold LE, Kleykamp D, Votolato N, Gibson RA, Horrocks L. "Potential link between dietary intake of fatty acid and behavior: pilot exploration of serum lipids in attention-deficit hyperactivity disorder." *J Child Adolesc Psychopharmacol* . 1994;4(3):171-182.

Sinn, N and Bryan, J, "Effect of Supplementation with Polyunsaturated Fatty Acids and Micronutrients on Learning and Behavior Problems Associated with Child ADHD," *Journal of Developmental & Behavioral Pediatrics*. 28(2):82-91, April 2007

M.G. Aman, E. A. Mitchell, S.H. Turbott, "The effects of essential fatty acid supplementation by Efamol in hyperactive children," *J. Abnorm Child Psychol* 1987; 15: 75-90.

- R. J. Prinz et al., "Dietary correlates of hyperactive behaviour in children," *Journal of Consulting Clin Psychol*, Vol 48, 1980, pp. 760-69
- I. Colquhoun and S. Bunday, "A lack of essential fats as a possible cause of hyperactivity in children," *Medical Hypotheses*, Vol 7, 1981, pp. 673-9
- L. J. Stevens et al., "Essential fat metabolism in boys with attention-deficit hyperactivity disorder," *Am J Clin Nutr*, Vol 65, 1995, pp. 761-8
- J. R. Burgess, "ADHD: observational and interventional studies," *NIH workshop on omega-3 EFAs in psychiatric disorder*, National Institutes of Health, Bethesda, Maryland, 1998
- Burgess, John R., Laura Stevens, et al., "Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder." *American Journal of Clinical Nutrition*, 2000;71 (supplement):327-329.
- A. J. Richardson et al., "Treatment with highly unsaturated fatty acids can reduce ADHD symptoms in children with specific learning difficulties: a randomised controlled trial," paper given at British Dyslexia Association International Conference, University of York, April 2001
- A. Richardson and B. Puri, "A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties," *Prog Neuropsychopharmacol Biol Psychiatry*, Vol 26(2), 2002, pp. 233-9
- A. Richardson and B. Puri, "A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD," *Prog Neuropsychopharmacol Biol Psychiatry*, 2002
- Richardson, A.J. 2006. "Omega-3 fatty acids in ADHD and related neurodevelopmental disorders." *Int.Rev.Psychiatry* 18(2):155-172.
- Richardson, A.J., and M.A. Ross. 2000. "Fatty acid metabolism in neurodevelopmental disorder: a new perspective on associations between attention-deficit/hyperactivity disorder, dyslexia, dyspraxia and the autistic spectrum." *Prostaglandins Leukot. Essent. Fatty Acids* 63(1-2):1-9.
- N. I. Ward, "Assessment of clinical factors in relation to child hyperactivity," *J Nutr Environ Med*, Vol 7, 1997, pp. 333-342
- R. J. Theil, "Nutrition based interventions for ADD and ADHD," *Townsend Letter for Doctors & Patients*, April 2000, pp. 93-5

Aggression

- Hamazaki, T., et al., (1996). "The effect of docosahexaenoic acid on aggression in young adults: a placebo-controlled double-blind study." *Journal of Clinical Investigation*, 97, 1129-1133.

- Bugajski J (1996): "Role of prostaglandins in the stimulation of the hypothalamic-pituitary-adrenal axis by adrenergic and neurohormone systems." *J Physiol Pharmacol* 47:559–575.
- Buydens-Branchey L, Branchey M, McMakin DL, Hibbeln JR (2003): "Polyunsaturated fatty acid status and aggression in cocaine addicts." *Drug Alcohol Depend* 71:319–323.
- George DT, Hibbeln JR, Ragan PW, Umhau JC, Phillips MJ, Doty L, et al (2000): "Lactate-induced rage and panic in a select group of subjects who perpetrate acts of domestic violence." *Biol Psychiatry* 47:804–812.
- Gesch CB, Hammond SM, Hampson SE, Eves A, Crowder MJ (2002): "Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners. Randomised, placebocontrolled trial." *Br J Psychiatry* 181:22–28.
- Hamazaki T, Sawazaki S, Kobayashi M (1996): "The effect of docosahexaenoic acid on aggression in young adults. A double-blind study." *J Clin Invest* 97:1129–1134.
- Hamazaki T, Thienprasert A, Kheovichai K, Samuhaseneetoo S, Nagasawa T, Watanabe S (2002): "The effect of docosahexaenoic acid on aggression in elderly Thai subjects—a placebo-controlled double-blind study." *Nutr Neurosci* 5:37–41.
- Hibbeln JR (2001): "Seafood consumption and homicide mortality." *World Rev Nutr Diet* 85:41–46.
- Iribarren C, Markovitz JH, Jacobs DR, Schreiner PJ, Daviglius M, Hibbeln JR (2004): "Dietary intake of n-3, n-6 fatty acids and fish: Relationship with hostility in young adults—the CARDIA study." *Eur J Clin Nutr* 58:24–31.
- Takeuchi T, Iwanaga M, Harada E (2003): "Possible regulatory mechanism of DHA-induced anti-stress reaction in rats." *Brain Res* 964:136–143.
- Van Praag HM (2001): "Anxiety/aggression-driven depression: a paradigm of functionalization and verticalization of psychiatric diagnosis." *Prog Neuropsychopharmacol Biol Psychiatry* 25:893–924.

Alzheimers

- Soderberg M, Edlund C, Kristennson K, et al., "Fatty acid composition of brain phospholipids in aging and Alzheimer's disease." *Lipids*. 1991; 26:421-415.
- Kalmijn, S., et al., "Dietary fat intake and the risk of incident dementia in the Rotterdam Study," *Annals of Neurology* 42, 1997: p776-782.
- Cenacchi, T, et al. "Cognitive decline in the elderly. A double-blind placebo-controlled multicenter study on efficacy of phosphatidyl serine administration." *Aging Clin Exp Res* 1993;5:123-33.
- Song C, Horrobin D (2004): "Omega-3 fatty acid ethyl-eicosapentaenoate, but not soybean oil, attenuates memory impairment induced by central IL-1beta administration." *J Lipid Res* 45:1112–1121.

Anxiety

George Mamalakis, et al., "Anxiety and Adipose Essential Fatty Acid Precursors for Prostaglandin E1 and E2," *Journal of the American College of Nutrition*, Vol. 17, No. 3, 239-243 (1998)

Charney DS, Deutch A (1996): "A functional neuroanatomy of anxiety and fear: Implications for the pathophysiology and treatment of anxiety disorders." *Crit Rev Neurobiol* 10:419–446.

Delarue J, Matzinger O, Binnert C, Schneiter P, Chiolero R, Tappy L (2003): "Fish oil prevents the adrenal activation elicited by mental stress in healthy men." *Diabetes Metab* 29:289 –295.

Autism

S. Vancassel, G. Durand, C. Barthelemy, B. Lejeune, J. Marineau, D. Guilloteau, C. Andres, S. Chalon, "Plasma fatty acid levels in autistic children," *Prostaglandins Leukot Essent Fatty Acids* 2001 65:1-7.

Bell, J.G., Dick, J.R., MacKinlay, E.E., Glen, A.C.A., MacDonald, D.J., Boyle, R.M. and Riordan, D.V. (2002), "Abnormal fatty acid metabolism in autism and Asperger's syndrome." *Phospholipid Spectrum Disorder in Psychiatry and Neurology* (2nd edition) "in press".

Bell, J.G., et al. 2004. "Essential fatty acids and phospholipase A2 in autistic spectrum disorders." *Prostaglandins Leukot.Essent.Fatty Acids* 71(4):201-204.

Johnson, S.M., and E. Hollander. 2003. "Evidence that eicosapentaenoic acid is effective in treating autism." *J Clin Psychiatry* 64(7):848-849.

Green, V.A., K.A. Pituch, J. Itchon, A. Choi, M. O'Reilly, J. Sigafos, "Internet survey of treatments used by parents of children with autism," *Res Dev Disabil*, 2006, 27(1):70-84.

Bipolar Disorder

Gershon, Elliot et al. "Birth-cohort changes in manic and depressive disorders in relatives of bipolar and schizoaffective patients." *Archives of General Psychiatry* 44 (1987):314-319.

Hibbeln, Joseph., "Fish consumption and major depression," *The Lancet* 351 (1998):1213.

Horrobin, David. "Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, aging and osteoporosis: possible candidate genes." *Prostaglandins, Leukotrienes and Essential Fatty Acids* 60 (1999): 217-234.

Kane, Edward, "Fats: The Inside Story," *BodyBio*, 1999.

Klerman, Gerald L. et al, "Birth cohort trends in rates of major depressive disorder among relatives of patients with affective disorder," *Archives of General Psychiatry* 42 (1985):689-693.

Richardson, A. J. et al., "Fatty acid deficiency signs predict the severity of reading and related difficulties in dyslexic children," *Prostaglandins, Leukotrienes and Essential Fatty Acids* 63 (2000): 69-74.

Simouopoulos, Artemis P. *The Omega Diet*. New York: Harper Collins, 1999.

Stevens L.J. and SS Zentall et al. "Omega-3 fatty acids in boys with behavior, learning and health problems." *Physiological Behavior* April-May (1996):915-920.

Stoll, Andrew. "Omega 3 fatty acids in bipolar disorder: A preliminary, double-blind, placebo-controlled trial." *Archives of General Psychiatry* 56 (May 1999): 407-412.

Stoll, Andrew. *The Omega Connection*. New York: The Free Press, 2001.

Borderline Personality Disorder (BPD)

Zanarini MC, Frankenburg FR., "Omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study," *Am J Psychiatry* 2003 Jan;160(1):167-9

Chronic Fatigue Syndrome

Reid, S., et al., "Chronic fatigue syndrome," *British Medical Journal*, 2000. 320(7230): p. 292-6.

Verillo, E.F. and L.M. Gellman, *Chronic Fatigue Syndrome*. 1997, New York: St Martin's Griffin.

Manian, F.A., "Simultaneous measurement of antibodies to Epstein-Barr virus, human herpesvirus 6, herpes simplex virus types 1 and 2, and 14 enteroviruses in chronic fatigue syndrome: is there evidence of activation of a nonspecific polyclonal immune response?" *Clin Infect Dis*, 1994. 19(3): p. 448-53.

Buchwald, D., et al., "Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome," *J Rheumatol*, 1997. 24(2): p. 372-6.

Horrobin, D.F., "Post-viral fatigue syndrome, viral infections in atopic eczema, and essential fatty acids," *Med Hypotheses*, 1990. 32(3): p. 211-7.

Gray, J.B. and A.M. Martinovic, "Eicosanoids and essential fatty acid modulation in chronic disease and the chronic fatigue syndrome," *Med Hypotheses*, 1994. 43(1): p. 31-42.

Behan, P.O., W.M. Behan, and D. Horrobin, "Effect of high doses of essential fatty acids on the postviral fatigue syndrome," *Acta Neurol Scandinavia*, 1990. 82(3): p. 209-16.

Warren, G., M. McKendrick, and M. Peet, "The role of essential fatty acids in chronic fatigue syndrome. A case-controlled study of red-cell membrane essential fatty acids (EFA) and a placebo-controlled treatment study with high dose of EFA," *Acta Neurol Scand*, 1999. 99(2): p. 112-6.

Sammon, A.M., "Dietary linoleic acid, immune inhibition and disease," *Postgrad Med J*, 1999. 75(881): p. 129-32.

Wallace, F.A., et al., "Dietary fatty acids influence the production of Th1- but not Th2-type cytokines," *J Leukoc Biol*, 2001. 69(3): p. 449-57.

Werbach, M.R., "Nutritional strategies for treating chronic fatigue syndrome," *Altern Med Rev*, 2000. 5(2): p. 93-108.

Logan, A.C. and C. Wong, "Chronic fatigue syndrome: oxidative stress and dietary modifications," *Altern Med Rev*, 2001. 6(5): p. 450-9.

Depression

Banki CM, Karmacsi L, Bissette G, Nemeroff CB (1992): "CSF corticotropinreleasing hormone and somatostatin in major depression: Response to antidepressant treatment and relapse." *Eur Neuropsychopharmacol* 2:107-113.

Hanah Nemets, et al, "Omega-3 Treatment of Childhood Depression: A Controlled, Double-Blind Pilot Study," *Am J Psychiatry* 2006 163: 1098-1100.

Gordon Parker et al, "Omega-3 Fatty Acids and Mood Disorders," *Am J Psychiatry* 2006 163: 969-978.

M. Elizabeth Sublette et al, "Omega-3 Polyunsaturated Essential Fatty Acid: Status as a Predictor of Future Suicide Risk," *Am J Psychiatry* 163:1100-1102, June 2006

J.R. Hibbeln, "Long-chain polyunsaturated fatty acids in depression and related conditions," *Phospholipid Spectrum Disorder*, M. Peet, I. Glen, and D. Horrobin, eds. Lancashire, England: Marius Press, 1999, 195-210.

J.R. Hibbeln, "Fish consumption and major depression," *Lancet* 1998 351:1213.

Peet et al, "EPA for unipolar major depression," *presented at Biological Psychiatry* 2001.

Nemets et al. "Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder," *Am. J. Psychiatry* 2002 159:477-479.

Marangell et al., "DHA in unipolar major depression," *presented at ISSFAL*, Tsukuba, Japan 2000.

Bruinsma KA, Taren DL. "Dieting, essential fatty acid intake, and depression." *Nutrition Rev.* 2000;58(4):98-108.

Su K.P., et al., "Omega-3 fatty acids in major depressive disorder: a preliminary double-blind, placebo-controlled trial," *European Neuropsychopharmacology* 13, 2003, p 267-271.

Diabetic Neuropathy

"Long-term Effects of Eicosapentaenoic Acid (EPA) on Diabetic Peripheral Neuropathy and Serum Lipids in Patients with Type II Diabetes Mellitus," *Journal of Diabetes and its Complications* 1996; 10 (5): 280-287

"The Use of Gamma-linolenic Acid in Diabetic Neuropathy," *Agents Actions Suppl* 1992; 37: 120-44

“Dietary Omega-3 Fatty Acid Deficiency and Visual Loss in Infant Rhesus Monkeys,” *J Clin Invest* 1984 (Jan); 73 (1): 272–6

NE Cameron, MA Cotter and S Robertson, “Essential fatty acid diet supplementation. Effects on peripheral nerve and skeletal muscle function and capillarization in streptozocin-induced diabetic rats,” *Diabetes*, Vol 40, Issue 5 532-539,

Head RJ, McLennan PL, Raederstorff D, Muggli R, Burnard SL, McMurchie EJ., “Prevention of nerve conduction deficit in diabetic rats by polyunsaturated fatty acids.” *Am J Clin Nutr* . 2000;71:386S-392S.

Keen H, Payan J, Allawi J, et al. “Treatment of diabetic neuropathy with gamma-linolenic acid. The Gamma-Linolenic Acid Multicenter Trial Group.” *Diabetes Care* . 1993;16(1):8-15.

Learning Disabilities

Belzung, C., et al. (1998). “Alpha-linolenic acid deficiency modifies distractibility but not anxiety and locomotion in rats during aging.” *Journal of Nutrition*, 128(9), 1537-1542.

Gamoh, S., et al., (1999). “Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats.” *Neuroscience*, 93, 237-241.

Richardson, A.J. & Puri, B.K. (2002). “A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties.” *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 26, 233-239.

Stordy, J. (2000). “Dark adaptation, motor skills, docosahexaenoic acid, and dyslexia.” *American Journal of Clinical Nutrition*, 71(1), 323-326.

Schizophrenia

Richardson AJ, Easton T, Puri BK., “Red cell and plasma fatty acid changes accompanying symptom remission in a patient with schizophrenia treated with eicosapentaenoic acid.” *European Neuropsychopharmacology*. 10(3):189-93

M. Peet, J.D. E. Laugharne, N. Rangarajan, D. Horrobin, G. Reynolds, “Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients,” *J. Psychiatry Res* 1995 29:227—232.

J.K. Yao, D.P. Van Kammen, J.A. Welker “Red blood cell membrane dynamics in schizophrenia II Fatty acid composition.” *Schizophr Res*. 1994 13:216-226.

M.M. Khan, D.R. Evans, V. Gunna, R.E. Scheffer, V.V. Parikh, S. P. Mahadik, “Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics.”

W.S. Fenton, J. Hibbeln, M. Knable, “Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of Schizophrenia.” *Bio. Psychiatry* 2000 47:8-21.

M. Peet, J.D. E. Laugharne, J. Mellor, C.N. Ramchand, "Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation." *Prostaglandins Leukot Essent Fatty Acids* 1996 55:71-75.

J.E. Mellor, J.D. E. Laugharne, M. Peet, "Omega-3 fatty acid supplementation in schizophrenic patients." *Human psychopharmacol* 1996 11:39-46

Ohara, K. "The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia." *Prog Neuropsychopharmacol Biol Psychiatry*. 2007 Mar 30;31(2):469-74.

Christensen O and Christensen E., "Fat consumption and schizophrenia." *Acta Psychiatr Scand* 1988;78:586-91.

Miscellaneous

Van Vliet, T. and Katan, M.B. 1990. "Lower ratio of n-3 to n-6 fatty acids in cultured than in wild fish." *Am. J. Clin. Nutr.* 51: 1-2.

A.P. Simopoulos, "The importance of the ratio of omega-6/omega-3 essential fatty acids," *Biomed Pharmac* 2002 56:365-379.

E.E. Birch, D.G. Birch, D.R. Hoffman, R. Uauy, "Dietary essential fatty acid supply and visual acuity development," *Invest Ophthalmol Vis Sci* 1992 33:3242-3253.

C. Agostoni, E. Riva, S. Trojan, R. Bellu, M. Giovanni, "Docosahexanoic acid status and development quotient of healthy term infants." *Lancet* 1995 346: 638.

M.G. Murphy "Dietary fatty acids and membrane protein function," *J. Nutr. Biochem* 1990 1:68-78

J.M. Bourre, M. Francois, A. Youyou, M. Dumond, M. Piciotti, G. Pascal, et al. "The effects of dietary alpha-linolenic acid on the composition of nerve membranes, enzymatic activity, amplitude of electrophysiological parameters, resistance to poisons and performance of learning tasks in rats." *J. Nutr* 1989 119:1880-1892.

T.J. Stradomska, A. Tylki-Szymanska, Z. Bentkowski, "Very long-chain fatty acids in Rett syndrome." *Eur J. Pediatr* 1999 158:226-229.

R. Shoda, K. Matsueda, S. Yamato, N. Umeda Epidemiologic analysis of Crohn's disease in Japan: Japan Aam. *J. Clin. Nutr.* 1996 63:741-745.

A. Belluzi, C. Brignola, M. Campieri, et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease, *N. Engl J. Med.* 1996 334:1557-1560.

W.E.M. Lands (1992). "Biochemistry and physiology of n-3 fatty acids." *FASEB J* 6: 2530-2536.

Catherine H. MacLean, MD, PhD et al (January 2006). "Effects of Omega-3 Fatty Acids on Cancer Risk". *Journal of the American Medical Association* 295 (4): 403-415.

Lee Hooper et al (April 2006). "Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review" *British Medical Journal* 332: 752-760.

- Wang C, Harris WS, Chung M, et al., "N-3 fatty acids from fish or fish-oil supplements but not a-linoleic acid, benefit cardiovascular outcomes in primary and secondary prevention studies: a systematic review." *Am J. Clin Nutr* 2006;84:5-17
- Mozaffarian D, & Rimm EB. "Fish Intake, Contaminants, and Human Health: Evaluating the Risks and the Benefits." *JAMA*, October 18, 2006—Vol 296, No. 15
- MCKENNEY, J. and SICA, D, "Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia," *American Journal of Health-System Pharmacy*. 646:595-605, March 15, 2007 2.
- Yokoyama M et al., "Effects of eicosapentaenoic acid on major coronary events in hypercholesterolemic patients (JELIS): a randomized open-label, blinded endpoint analysis," *Lancet* 2007 3.
- Damsgaard C, Lauritzen L, Kjær T, Holm P, Fruekilde M, Michaelsen K and Frøkiær H, "Fish Oil Supplementation Modulates Immune Function in Healthy Infants," *J. Nutr.* 137:1031-1036, April 2007
- Lee D, Lee I, Jin S, Steffes M, Jacobs D, "Association Between Serum Concentrations of Persistent Organic Pollutants and Insulin Resistance Among Nondiabetic Adults," *Diabetes Care* 30:622-628, 2007
- Kris-Etherton P, Eckel RH, Howard BV, St. Jeor S, Bazzare TL. "AHA Science Advisory: Lyon Diet Heart Study. Benefits of a Mediterranean-style Dietary Pattern on Cardiovascular Disease. *Circulation* 2001;103:1823
- Lands WEM. "Diets could prevent many diseases." *Lipids* 2003;38(4): 317-321
- Zambón D, Sabate J, Munoz S, et al. "Substituting walnuts for monounsaturated fat improves the serum lipid profile of hypercholesterolemic men and women." *Ann Intern Med*. 2000;132:538-546.
- Young, G., and J. Conquer. 2005. "Omega-3 fatty acids and neuropsychiatric disorders." *Reprod.Nutr.Dev* 45(1):1-28.
- Genuis, S.J.a.G.K.S. 2006. "Time for an oil check: the role of essential omega-3 fatty acids in maternal and pediatric health." *Journal of Perinatology* 26:359-365.
- Olsen SF, Secher NJ. "Low consumption of seafood in early pregnancy as a risk factor for preterm delivery: prospective cohort study." *BMJ* 2002; 324: 1–5
- Odent M, Colson S, De Reu P. "Consumption of seafood and preterm delivery. Encouraging pregnant women to eat fish did not show effect." *BMJ*. 2002 May 25;324(7348):1279
- Simopoulos AP, Cleland LG (eds): "Omega-6/omega-3 Essential Fatty Acid Ratio: The Scientific Evidence." *World Rev Nutr Diet*. Basel, Karger, 2003, Vol 92.
- Okuyama H. "High n-6 to n-3 ratio of dietary fatty acids rather than serum cholesterol as a major risk factor for coronary heart disease." *Eur J Lipid Sci Technol*. 2001; 103:418-22.
- Robson, A. 2006. "Shellfish view of omega-3 and sustainable fisheries." *Nature* 444, 1002 Shellfish in NATURE

- Robson, A. 2007. "Preventing the diseases of civilisation: shellfish, the omega-3:6 balance and human health." *Shellfish News* 23, 25-27 Shellfish and Health
- Cunnane SC (2006) "Survival of the fattest: the key to human brain evolution." *M S-MEDICINE SCIENCES* 22 (6-7): 659-663.
- Genuis, S.J.a.G.K.S. 2006. "Time for an oil check: the role of essential omega-3 fatty acids in maternal and pediatric health." *Journal of Perinatology* 26:359-365.
- Young, G., and J. Conquer. 2005. "Omega-3 fatty acids and neuropsychiatric disorders." *Reprod.Nutr.Dev* 45(1):1-28.
- Hibbeln JR, Nieminen LR, Blasbalg TL, Riggs JA, Lands WE. "Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity." *Am J Clin Nutr.* 2006 Jun;83(6 Suppl):1483S-1493S.
- al-Sabanah OA. "Effect of evening primrose oil on gastric ulceration and secretion induced by various ulcerogenic and necrotizing agents in rats." *Food Chem Toxicol* . 1997;35(8):769-775.
- Barham JB, Edens MB, Fonteh AN, Johnson MM, Easter L, Chilton FH. Addition of eicosapentaenoic acid to gamma-linolenic acid-supplemented diets prevents serum arachidonic acid accumulation in humans. *J Nutr* . 2000;130(8):1925-1931.
- Barre DE. Potential of evening primrose, borage, black currant, and fungal oils in human health. *Ann Nutr Metab.* 2001;45(2):47-57
- Belch JJ, Hill A. Evening primrose oil and borage oil in rheumatologic conditions. *Am J Clin Nutr* . 2000;71(1 Suppl):352S-356S.
- Bendich A. The potential for dietary supplements to reduce premenstrual syndrome (PMS) symptoms. *J Am Coll Nutr* . 2000;19(1):3-12.
- Brown NA, Brown AJ, Harding JJ, Dewar HM. Nutrition supplements and the eye. *Eye* . 1998; 12(pt. 1):127-133.
- Calder PC, Miles EA. Fatty acids and atopic disease. *Pediatr Allergy Immunol* . 2000;11 Suppl 13:29-36.
- Calder PC, Zurier RB. Polyunsaturated fatty acids and rheumatoid arthritis. *Curr Opin Clin Nutr Metab Care* . 2001;4(2):115-121.
- Chenoy R, Hussain S, Tayob Y, O'Brien PM, Moss MY, Morse PF. Effect of oral gamma-linolenic acid from evening primrose oil on menopausal flushing. *BMJ.* 1994;19(308):501-503.
- Corbett R, Menez JF, Flock HH, Leonard BE. The effects of chronic ethanol administration on rat liver and erythrocyte lipid composition: modulatory role of evening primrose oil. *Alcohol Alcohol.* 1991;26(4):459-464.
- Darlington LG, Stone TW. Antioxidants and fatty acids in the amelioration of rheumatoid arthritis and related disorders. *Br J Nutr* . 2001;85(3):251-269.

- Davies CL, Loizidou M, Cooper AJ, et al. Effect of gamma-linolenic acid on cellular uptake of structurally related anthracyclines in human drug sensitive and multidrug resistant bladder and breast cancer cell lines. *Eur J Cancer* . 1999;35:1534-1540.
- Engler MM, Schambelan M, Engler MB, Ball DL, Goodfriend TL. Effects of dietary gamma-linolenic acid on blood pressure and adrenal angiotensin receptors in hypertensive rats. *Proc Soc Exp Biol Med* . 1998;218(3):234-237.
- Fan YY, Chapkin RS. Importance of dietary gamma-linolenic acid in human health and nutrition. *J Nutr* . 1998; 128(9): 1411-1414.
- Frenoux JMR, Prost ED, Belleville JL, Prost JL. A polyunsaturated fatty acid diet lowers blood pressure and improves antioxidant status in spontaneously hypertensive rats. *J Nutr* . 2001;131(1):39-45.
- Furse RK, Rossetti RG, Zurier RB. Gammalinolenic acid, an unsaturated fatty acid with anti-inflammatory properties, blocks amplification of IL-1 beta production by human monocytes. *J Immunol* . 2001;167(1):490-496.
- Garcia CM, et al. Gamma linolenic acid causes weight loss and lower blood pressure in overweight patients with family history of obesity. *Swed J Biol Med* . 1986;4:8-11.
- Giamarellos-Bourboulis EJ, Grecka P, Dionyssiou-Asteriou A, et al. In vitro interactions of gamma-linolenic acid and arachidonic acid with ceftazidime on multiresistant *Pseudomonas aeruginosa*. *Lipids* . 1999;34:S151-152.
- Graham-Brown R. Atopic dermatitis: unapproved treatments or indications. *Clin Dermatol*. 2000;18(2):153-158.
- Grattan C, Burton JL, Manku M, Stewart C, Horrobin DF. Essential-fatty-acid metabolites in plasma phospholipids in patients with ichthyosis vulgaris, acne vulgaris and psoriasis. *Clin Exp Dermatol* . 1990;15(3):174-176.
- Griffini P, Fehres O, Klieverik L, et al. Dietary W-3 polyunsaturated fatty acids promote colon carcinoma metastasis in rat liver. *Cancer Res* . 1998;58:3312-3319.
- Hederos CA, Berg A. Epogam evening primrose oil treatment in atopic dermatitis and asthma. *Arch Dis Child* . 1996;75(6):494-497
- Holman RT, Adams CE, Nelson RA, et al. Patients with anorexia nervosa demonstrate deficiencies of selected essential fatty acids, compensatory changes in nonessential fatty acids and decreased fluidity of plasma lipids. *J Nutr*. 1995;125:901-907.
- Horrobin DF. The role of essential fatty acids and prostaglandins in the premenstrual syndrome . *J Reprod Med* . 1983;28(7):465-468.
- Ikushima S, Fujiwara F, Todo S, Imashuku S. Gamma linolenic acid alters the cytotoxic activity of anticancer drugs on cultured human neuroblastoma cells. *Anticancer Res*. 1990;10:1055-1059.

- Kankaanpaa P, Nurmela K, Erkkila A, et al. Polyunsaturated fatty acids in maternal diet, breast milk, and serum lipid fatty acids of infants in relation to atopy. *Allergy*. 2001;56(7):633-638.
- Kast RE. Borage oil reduction of rheumatoid arthritis activity may be mediated by increased cAMP that suppresses tumor necrosis factor-alpha. *Int Immunopharmacol* . 2001;1(12):2197-2199.
- Kenny FS, Pinder SE, Ellis IO et al. Gamma linolenic acid with tamoxifen as primary therapy in breast cancer. *Int J Cancer* . 2000;85:643-648.
- Kris-Etherton PM, Taylor DS, Yu-Poth S, et al. Polyunsaturated fatty acids in the food chain in the United States. *Am J Clin Nutr* . 2000;71(1 Suppl):179S-188S.
- Kruger MC, Coetzer H, de Winter R, Gericke G, van Papendorp DH. Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis. *Aging Clin Exp Res* . 1998;10:385-394.
- Kruger MC, Horrobin DF. Calcium metabolism, osteoporosis and essential fatty acids: a review. *Prog Lipid Res* . 1997;36:131-151.
- Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis with black currant seed oil. *Br J Rheumatol* . 1994;33(9):847-852.
- Leng GC, Lee AJ, Fowkes FG, et al. Randomized controlled trial of gamma-linolenic acid and eicosapentaenoic acid in peripheral arterial disease. *Clin Nutr* . 1998;17(6):265—271,
- Little C, Parsons T. Herbal therapy for treating rheumatoid arthritis. *Cochrane Database Syst Rev* . 2001;(1):CD002948.
- Madhavi N, Das UN. Effect of n-6 and n-3 fatty acids on the survival of vincristine sensitive and resistant human cervical carcinoma cells in vitro. *Cancer Lett* . 1994;84:31-41.
- Manjari V, Das UN. Effect of polyunsaturated fatty acids on dexamethasone-induced gastric mucosal damage. *Prostaglandins Leukot Essent Fatty Acids* . 2000;62(2):85-96.
- McCarty MF. Nutritional modulation of mineralocorticoid and prostaglandin production: potential role in prevention and treatment of gastric pathology. *Med Hypotheses* . 1983;11(4):381-389,
- Menendez JA, del Mar Barbacid M, Montero S, et al. Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. *Eur J Cancer* . 2001;37:402-413.
- Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. *Arch Intern Med* . 1998;158(20):2200–2211.
- Mitchell EA, Aman MG, Turbott SH, Manku M. Clinical characteristics and serum essential fatty acid levels in hyperactive children. *Clin Pediatr (Phila)*. 1987;26:406-411.

- Morphake P, Bariety J, Darlametsos J, et al. Alteration of cyclosporine (CsA)-induced nephrotoxicity by gamma linolenic acid (GLA) and eicosapentaenoic acid (EPA) in Wistar rats. *Prostaglandins Leukot Essent Fatty Acids*. 1994;50:29-35.
- Morse PF, Horrobin DF, Manku MS, et al. Meta-analysis of placebo-controlled studies of the efficacy of Epogam in the treatment of atopic eczema: relationship between plasma essential fatty changes and treatment response. *Br J Dermatol* . 1989;121(1):75-90.
- Munoz SE, Lopez CB, Valentich MA, Eynard AR. Differential modulation by dietary n-6 or n-9 unsaturated fatty acids on the development of two murine mammary gland tumors having different metastatic capabilities. *Cancer Lett* . 1998;126:149-155.
- Paul KP, Leichsenring M, Pfisterer M, et al. Influence of n-6 and n-3 polyunsaturated fatty acids on the resistance to experimental tuberculosis. *Metabolism* . 1997;46(6):619-624.
- Plumb JA, Luo W, Kerr DJ. Effect of polyunsaturated fatty acids on the drug sensitivity of human tumour cell lines resistant to either cisplatin or doxorubicin. *Br J Cancer*. 1993;67:728-733.
- Richardson AJ, Puri BK. The potential role of fatty acids in attention-deficit/hyperactivity disorder. *Prostaglandins Leukot Essent Fatty Acids*. 2000;63(1/2):79-87.
- Rothman D, DeLuca P, Zurier RB. Botanical lipids: effects on inflammation, immune responses, and rheumatoid arthritis. *Semin Arthritis Rheum* . 1995;25(2):87-96.
- Shils ME, Olson JA, Shike M, Ross AC. *Modern Nutrition in Health and Disease* . 9th ed. Baltimore, Md: Williams & Wilkins; 1999:88-90, 1347-1348.
- Simopoulos AP. Essential fatty acids in health and chronic disease. *Am J Clin Nutr* . 1999;70(3 suppl):560S-569S.
- Soyland E, Funk J, Rajka G, et al. Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis. *N Engl J Med* . 1993;328(25):1845-1846.
- Stoll BA. Breast cancer and the Western diet: role of fatty acids and antioxidant vitamins. *Eur J Cancer* . 1998;34(12):1852-1856.
- Thompson L, Cockayne A, Spiller RC. Inhibitory effect of polyunsaturated fatty acids on the growth of *Helicobacter pylori*: a possible explanation of the effect of diet on peptic ulceration. *Gut* . 1994;35(11):1557-1561.
- Tsai W-S, Nagawa H, Kaizaki S, Tsuruo T, Muto T. Inhibitory effects of n-3 polyunsaturated fatty acids on sigmoid colon cancer transformants. *J Gastroenterol* . 1998;33:206-212.
- Wainwright PE. Do essential fatty acids play a role in brain and behavioral development? *Neurosci Biobehav Rev* . 1992;16(2):193-205.

Wakai K, Okamoto K, Tamakoshi A, Lin Y, Nakayama T, Ohno Y. Seasonal allergic rhinoconjunctivitis and fatty acid intake: a cross-sectional study in Japan. *Ann Epidemiol* . 2001;11(1):59-64.

Werbach MR. *Nutritional Influences on Illness* . 3rd ed. Tarzana, Calif: Third Line Press; 1999:67-70, 89-103, 206-207, 358-362, 371, 445, 455, 471, 562-565, 622-623, 657-660, 666-670, 678-683.

Whitaker DK, Cilliers J, de Beer C. Evening primrose oil (Epogam) in the treatment of chronic hand dermatitis: disappointing therapeutic results. *Dermatology* . 1996;193(2):115-120.

Worm M, Henz BM. Novel unconventional therapeutic approaches to atopic eczema. *Dermatology* . 2000;201(3):191-195.

Wu D, Meydani M, Leka LS, et al. Effect of dietary supplementation with black currant seed oil in the immune response of healthy elderly subjects. *Am J Clin Nutr* . 1999;70:536-543.

Yam D, Eliraz A, Berry EM. Diet and disease – the Israeli paradox: possible dangers of high omega-6 polyunsaturated fatty acid diet. *Isr J Med Sci* . 1996;32(11):1134-1143.

Stordy BJ. Dark adaptation, motor skills, docosahexaenoic acid, and dyslexia. *Am J Clin Nutr*. 2000; 71:323S-326S.

Davidson MH, Maki KC, Kalkowski J, et al. Effects of docosahexaenoic acid on the serum lipoproteins with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial. *J Am Coll Nutr*. 1997; 16:236-243.

Eriksson PS, Perfilieva E, Bjork-Eriksson T, et al. Neurogenesis in the adult human hippocampus. *Nat Med*. 1998; 4:1313-1317.

Freedman SD, Katz MH, Parker EM, et al. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in mice. *Proc Natl Acad Sci USA*. 1999; 96:13995-14000.

Grimsgaard S, Bonna KH, Hansen J-B, Nordoy A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. *Am J Clin Nutr*. 1997; 66:649-959.

Horrocks LA, Yeo YK. Health benefits of docosahexaenoic acid. *Pharma Res*. 1999; 40:211-225.

Lucas A, Stafford M, Morley R, et al. Efficacy and safety of long-chain polyunsaturated fatty acid supplementation of infant-formula milk: a randomized trial. *Lancet*. 1999; 354:1948-1954

Madsen L, Rustan AC, Vaagenes H, et al. Eicosapentaenoic and docosahexaenoic acid affect mitochondrial and peroxisomal fatty acid oxidation in relation to substrate preference. *Lipids*. 1999; 34:951-963..

Martinez M, Vazquez E, Garcia-Silva MT, et al. Therapeutic effects of docosahexaenoic acid ethyl ester in patients with generalized peroxisomal disorders. *Am J Clin Nutr.* 2000; 71:376S-385S.

Nelson GJ, Schmidt PS, Bartolini GL, et al. The effect of dietary docosahexaenoic acid on platelet function, platelet fatty acid composition, and blood coagulation in humans. *Lipids.* 1997; 32:1129-1136.